Candida auris‒Associated Hospitalizations, United States, 2017-2022

Emerg Infect Dis. 2023 Jul;29(7):1485-1487. doi: 10.3201/eid2907.230540.

Abstract

Using a large US hospital database, we describe 192 Candida auris‒associated hospitalizations during 2017-2022, including 38 (20%) C. auris bloodstream infections. Hospitalizations involved extensive concurrent conditions and healthcare use; estimated crude mortality rate was 34%. These findings underscore the continued need for public health surveillance and C. auris containment efforts.

Keywords: Candida auris; United States; epidemiology; fungal infections; fungi; hospitalizations.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antifungal Agents / pharmacology
  • Antifungal Agents / therapeutic use
  • Candida auris
  • Candida*
  • Candidiasis, Invasive* / drug therapy
  • Hospitalization
  • Humans
  • United States / epidemiology

Substances

  • Antifungal Agents

Supplementary concepts

  • Candida auris infection